UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 9, 2015
CORTEX
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
1-16467 |
|
33-0303583 |
(State
or other jurisdiction |
|
(Commission |
|
(I.R.S
Employer |
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
126
Valley Road, Suite C
Glen
Rock, New Jersey |
|
07452 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (201) 444-4947
(Former
name or former address, if changed since last report.)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
7.01 Regulation FD Disclosure
On January
9, 2015, Cortex Pharmaceuticals, Inc. (the “Company”) announced that the Company’s Executive Chairman and
CEO, Dr. Arnold S. Lippa, Ph.D., will be presenting at Biotech Showcase 2015TM at the Parc 55 Wyndham San Francisco-Union
Square Hotel. Dr. Lippa is currently scheduled to present at 4:30 p.m. Pacific Standard Time on Tuesday, January 13, 2015. The
slide presentation that the Company will be using at the conference is attached as Exhibit 99.1 and is being furnished and not
filed pursuant to Item 7.01 of Form 8-K.
Item
8.01 Other Events
The information
provided in Item 7.01 is incorporated herein by reference. The presentation will be available by live webcast that can be accessed
by clicking on the investors tab on the Company’s web-site (www.cortexpharm.com) and following the links and instructions
or by going to http://edge.media-server.com/m/p/atkkzavz. The press release announcing the Company’s participation in the
conference is attached as Exhibit 99.2.
Item
9.01 Financial Statements and Exhibits
(d) Exhibits.
A list of
exhibits that are furnished and filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere in
this document, and is incorporated herein by reference.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
CORTEX PHARMACEUTICALS, INC. |
Date: January 13, 2015 |
|
|
|
By: |
/s/ Arnold S. Lippa |
|
|
Arnold S. Lippa |
|
|
President and Chief Executive Officer |
EXHIBIT
INDEX
Exhibit Number |
|
Exhibit Description |
|
|
|
99.1 |
|
Slide Presentation (furnished herewith). |
99.2 |
|
Press Release dated January 9, 2015. |
Exhibit
99.2
Cortex
Pharmaceuticals, Inc. to Present at 7th Annual Biotech Showcase 2015™
CEO
to Present Strategic Initiatives in Respiratory Disorders and Key Objectives
Glen
Rock, N.J., Jan. 9, 2015/Globe Newswire – Cortex Pharmaceuticals, Inc. (CORX) (“Cortex” or the “Company”),
a leader in developing drugs for respiratory disorders, particularly sleep apneas and drug-induced respiratory depression, announces
that it will be presenting at Biotech Showcase 2015™ (www.ebdgroup.com/bts/index.php). The conference is co-sponsored by
the EBD Group and Demy-Colton Life Sciences Advisors and will be held at the Parc 55 Wyndham San Francisco-Union Square Hotel
in San Francisco, California from January 12 – 15, 2015.
The
Company’s Executive Chairman and CEO, Dr. Arnold S. Lippa, Ph.D., is currently scheduled to present at 4:30 p.m. Pacific
Standard Time on Tuesday, January 13, 2015. Dr. Lippa will present details of Cortex’s initiatives with dronabinol for obstructive
sleep apnea (Phase - IIB), CX-1739 (oral) for drug-induced respiratory depression and central sleep apnea (both Phase - IIa),
and CX-1942 (injectable) for drug-induced respiratory depression (preclinical), as well as background data.
The
conference is attended by public companies, institutional investors, industry executives, private equity firms, private companies,
venture capitalists, business development executives and sophisticated private investors.
The
presentation will be available by live webcast streaming online. To access the live audio webcast, log onto Cortex’s website
at www.cortexpharm.com, click on the investors tab and follow the links and instructions, or go to http://edge.media-server.com/m/p/atkkzavz.
A copy of the slide presentation to be presented at the conference will be filed with the Securities and Exchange Commission in
a Current Report on Form 8-K prior to the presentation and will also be available in the investors section of Cortex’s website.
About
Cortex Pharmaceuticals, Inc.
Cortex
Pharmaceuticals, Inc. is a biopharmaceutical company currently engaged in the discovery and development of drugs for the treatment
of respiratory disorders. Drug candidates are currently derived from two platforms, as described below.
The
first platform is a class of compounds known as ampakines that act as positive allosteric modulators of AMPA glutamate receptors.
Several ampakines in both oral and injectable form are being developed by Cortex for the treatment of drug induced respiratory
depression caused by opiates and anesthetics. In preclinical and clinical studies, such drugs have shown preliminary efficacy
in central sleep apnea and restored normal respiration without altering the analgesic effects of opiates or the anesthetic effects
of drugs such as propofol. The Company’s compounds belong to a new generation of ampakines that do not display the undesirable
side effects displayed by previous compounds.
The
second platform is the class of compounds known as cannabinoids, in particular, dronabinol. In a double-blind, placebo-controlled,
dose-ascending Phase 2A clinical study conducted by the Company, dronabinol significantly improved measures of sleep apnea in
a group of patients with obstructive sleep apnea. A larger 120 patient, double-blind, placebo-controlled Phase 2B study is currently
being conducted by the University of Illinois and is being funded by the National Institutes of Health.
Additional
information about Cortex and the matters discussed herein can be obtained on the Company’s website at www.cortexpharm.com
or in the Company’s filings on EDGAR at www.sec.gov.
Special
Note Regarding Forward-Looking Statements: Certain statements included or incorporated by reference in this news release,
including information as to the future financial or operating performance of the Company and its drug development programs, constitute
forward-looking statements. The words “believe,” “expect,” “anticipate,” “contemplate,”
“target,” “plan,” “intend,” “continue,” “budget,” “estimate,” “may,”
“schedule” and similar expressions identify forward-looking statements. Forward-looking statements include, among other
things, statements regarding future plans, targets, estimates and assumptions. Forward-looking statements are necessarily based
upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant
business, economic and competitive uncertainties and contingencies. Many factors could cause the Company’s actual results to differ
materially from those expressed or implied in any forward-looking statements made by, or on behalf of, the Company. Due to these
various risks and uncertainties, actual events may differ materially from current expectations. Investors are cautioned that forward-looking
statements are not guarantees of future performance and, accordingly, investors are cautioned not to put undue reliance on forward-looking
statements due to the inherent uncertainty therein. Forward-looking statements are made as of the date of this news release and
the Company disclaims any intent or obligation to update publicly such forward-looking statements, whether as a result of new
information, future events or results or otherwise.
Company
Contact:
Jeff
Margolis
Vice-President
and Secretary
Telephone:
(917) 834-7206
E-mail:
jmargolis@cortexpharm.com
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
過去 株価チャート
から 6 2024 まで 7 2024
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
過去 株価チャート
から 7 2023 まで 7 2024